New Potent EV-A71 Antivirals Targeting Capsid.
Hugo Roux,Franck Touret,Antonio Coluccia,Omar Khoumeri,Chaimae Majdi,Pietro Sciò,Romano Silvestri,Patrice Vanelle,Manon Roche
DOI: https://doi.org/10.1016/j.ejmech.2024.116658
IF: 7.088
2024-07-10
European Journal of Medicinal Chemistry
Abstract:The enterovirus is a genus of single-stranded, highly diverse positive-sense RNA viruses, including Human Enterovirus A-D and Human Rhinovirus A-C species. They are responsible for numerous diseases and some infections can progress to life-threatening complications, particularly in children or immunocompromised patients. To date, there is no treatment against enteroviruses on the market, except for polioviruses (vaccine) and EV-A71 (vaccine in China). Following a decrease in enterovirus infections during and shortly after the (SARS-Cov2) lockdown, enterovirus outbreaks were once again detected, notably in young children. This reemergence highlights on the need to develop broad-spectrum treatment against enteroviruses. Over the last year, our research team has identified a new class of small-molecule inhibitors showing anti-EV activity. Targeting the well-known hydrophobic pocket in the viral capsid, these compounds show micromolar activity against EV-A71 and a high selectivity index (SI) ( 5h : EC 50, MRC-5 = 0.57 μM, CC 50, MRC-5 >20 μM, SI >35; EC 50, RD = 4.38 μM, CC 50, RD > 40 μM, SI > 9; 6c : EC 50, MRC-5 = 0.29 μM, CC 50, MRC-5 >20 μM, SI >69; EC 50, RD = 1.66 μM, CC 50, RD > 40 μM, SI > 24; Reference: Vapendavir EC 50, MRC-5 = 0.36 μM, EC 50, RD = 0.53 μM, CC 50, RD > 40 μM, SI > 63). The binding mode of these compounds in complex with enterovirus capsids was analyzed and showed a series of conserved interactions. Consequently, 6c and its derivatives are promising candidates for the treatment of enterovirus infections.
chemistry, medicinal